Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors
CompanyDrug

Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors

Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation
CompanyDeals

Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation

Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development
CompanyDeals

Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development

Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis
CompanyDeals

Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis

Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer
CompanyDrug

Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer

China’s 11th National Centralized Drug Procurement Draft Unveils Major Pricing & Competition Reforms
Others

China’s 11th National Drug VBP Draft Unveils Major Pricing & Competition Reforms

Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib
CompanyDeals

Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib

Novo Nordisk Launches Company‑Wide Transformation to Drive Diabetes and Obesity Growth
Company

Novo Nordisk Launches Company‑Wide Transformation to Drive Diabetes and Obesity Growth

IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance
CompanyDeals

IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer
CompanyDrug

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer

Novartis Expands Iptacopan Approval to IgA Nephropathy in China
CompanyDrug

Novartis Expands Iptacopan Approval to IgA Nephropathy in China

Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection
CompanyDrug

Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection